Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Impact of MRD in FLT3+ AML: results from CHRYSALIS

Alexander Perl • 17 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Gilteritinib
CHRYSALIS

Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the results of the Phase I/II CHRYSALIS study (NCT02014558), specifically the impact of peripheral blood measurable residual disease (MRD) on overall survival following treatment with gilteritinib, the first single-agent therapy for relapsed/refractory acute myeloid leukemia (AML) patients with FLT3 mutations. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Perl suggests a potential association between an MRD negative status and longer survival in patients with FLT3-mutated AML.

More from Alexander Perl

3:03
QuANTUM-First: FLT3-ITD-specific MRD to assess benefits of quizartinib in FLT3-ITD+ AML
Alexander Perl • 9 Dec 2023
2:46
Update of the ADMIRAL trial: gilteritinib vs salvage chemotherapy prior to HSCT in FLT-3 mutated AML
Alexander Perl • 9 Dec 2023
2:07
Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML
Alexander Perl • 9 Jun 2023
0:44
The clinical meaning of MRD below the threshold of mCR in AML
Alexander Perl • 9 Jun 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals